Related Experiment Video
Updated: Jun 26, 2026
04:40
Venous Thrombosis Assay in a Mouse Model of Cancer
Published on: January 5, 2024
Thrombophilia and cancer
Netanel Horowitz1, Benjamin Brenner
1Thrombosis and Hemostasis Unit, Department of Hematology, Rambam Health Care Campus, Haifa, Israel.
Pathophysiology of Haemostasis and Thrombosis
|January 30, 2009
Summary
Cancer patients face higher risks of blood clots (venous thromboembolism). Inherited thrombophilia and antiphospholipid antibodies may increase this risk, but screening and prophylaxis strategies remain unclear.
Area of Science:
- Hematology
- Oncology
- Thrombosis Research
Background:
- Thrombophilia, both inherited and acquired, is a known risk factor for venous thromboembolism (VTE).
- Cancer patients exhibit a higher incidence of thrombotic events compared to the general population.
- Existing data on the interplay between inherited thrombophilia and cancer is limited and often shows varied results.
Purpose of the Study:
- To review the current understanding of inherited and acquired thrombophilia as risk factors for VTE in cancer patients.
- To discuss the implications of specific thrombophilic conditions, such as Factor V Leiden and antiphospholipid antibodies, in the context of cancer.
- To highlight the uncertainties surrounding screening and prophylaxis strategies for VTE in this high-risk population.
Main Methods:
- Literature review of existing studies on thrombophilia and cancer-associated VTE.
- Analysis of data concerning inherited thrombophilia (Factor V Leiden, prothrombin mutation) and acquired factors (antiphospholipid antibodies, hyperhomocysteinemia).
- Examination of VTE risk in cancer patients with central venous catheters and thrombophilia.
Main Results:
- Factor V Leiden and prothrombin mutation may elevate VTE risk in cancer patients.
- Antiphospholipid antibodies are prevalent in cancer patients, particularly those with lymphoproliferative diseases, and are associated with increased thrombotic risk (venous and arterial).
- Hyperhomocysteinemia is also noted as a potential risk factor.
Conclusions:
- Cancer patients with thrombophilia, especially those with central venous catheters, represent a high-risk group for VTE.
- The role and optimal management of screening for thrombophilia and initiating VTE prophylaxis in cancer patients remain subjects of ongoing investigation and debate.
- Further research is needed to clarify screening guidelines and establish effective prophylactic measures.
Related Concept Videos
01:30Anticoagulant Drugs: Low-Molecular-Weight Heparins
Hemostasis is a crucial process that prevents excessive blood loss from damaged blood vessels. It involves various mechanisms such as vasoconstriction, platelet adhesion and activation, and fibrin formation. The importance of each mechanism depends on the type of vessel injury. In contrast, thrombosis is the abnormal formation of a blood clot within the blood vessels, leading to potential complications if the clot obstructs blood flow. Thrombosis can be caused by increased coagulability of the...
01:24Disorders of Hemostasis
Hemostasis, the process that stops bleeding after a blood vessel injury, is crucial for maintaining the integrity of the circulatory system. However, disorders of hemostasis can disrupt this delicate balance, leading to either excessive clotting or bleeding. These disorders can be broadly classified into thromboembolic disorders and bleeding disorders.
Thromboembolic Disorders
Two factors primarily cause thromboembolic conditions.
Thromboembolic Disorders
Two factors primarily cause thromboembolic conditions.
01:30Venous Thrombosis I: Introduction
Venous thrombosis, the most common disorder of the veins, involves the formation of a thrombus or blood clot associated with vein inflammation. It can be classified as either superficial vein thrombosis or deep vein thrombosis.Superficial Vein Thrombosis: This involves the formation of a thrombus in a superficial vein, usually the greater or lesser saphenous vein. Though less severe than deep vein thrombosis (DVT), SVT can lead to complications if untreated.Deep Vein Thrombosis (DVT): This...
01:29Venous Thrombosis III: Interprofessional Care
Venous thrombosis requires effective prevention and treatment strategies to improve patient outcomes and reduce potential complications.Prevention StrategiesHealthcare providers must prioritize preventing venous thromboembolism (VTE) for all adult patients upon admission. Interventions depend on bleeding and thrombosis risk, medical history, current medications, diagnoses, planned procedures, and patient preferences. Patients on bed rest should change positions every two hours and, if not...
01:19Pulmonary Embolism I: Introduction
A blood clot, or thrombus, is a semi-solid mass composed of fibrin, platelets, and red blood cells. When it forms within a vessel, it can obstruct blood flow, known as thrombosis. If part of the clot detaches, it becomes an embolus that can travel and block distant vessels. When this occurs in the pulmonary arteries, it causes a condition known as pulmonary embolism (PE).Origin and ImpactMost often, the embolus originates from a thrombus in the deep veins of the lower limbs, a condition called...
01:29Pulmonary Embolism I: Introduction
Pulmonary embolism (PE) occurs when a thrombus, fat or air embolus, amniotic fluid, or tumor tissue blocks one or more pulmonary arteries. These blockages originate in the venous system or the right side of the heart.EtiologyPE primarily arises from deep vein thrombosis (DVT) and other hypercoagulable states, such as inherited thrombophilias. Additional etiological factors include venous stasis, commonly seen in obesity, and endothelial injury from surgery and trauma. Less common causes include...